BACKGROUND:Severe hepatotoxicity in people with human immunodeficiency virus (HIV) receivingefavirenz (EFV) has been reported. We assessed the incidence and risk factors of hepatotoxicity in women of childbearing age initiating EFV-containing regimens. METHODS: In the Promoting Maternal and Infant Survival Everywhere (PROMISE) trial, ART-naive pregnant women with HIV and CD4 count ≥ 350 cells/μL and alanine aminotransferase ≤ 2.5 the upper limit of normal were randomized during the antepartum and postpartum periods to antiretroviral therapy (ART) strategies to assess HIV vertical transmission, safety, and maternal disease progression. Hepatotoxicity was defined per the Division of AIDS Toxicity Tables. Cox proportional hazards models were constructed with covariates including participant characteristics, ART regimens, and timing of EFV initiation. RESULTS: Among 3576 women, 2435 (68%) initiated EFV at a median 121.1 weeks post delivery. After EFV initiation, 2.5% (61/2435) had severe (grade 3 or higher) hepatotoxicity with an incidence of 2.3 (95% confidence interval [CI], 2.0-2.6) per 100 person-years. Events occurred between 1 and 132 weeks postpartum. Of those with severe hepatotoxicity, 8.2% (5/61) were symptomatic, and 3.3% (2/61) of those with severe hepatotoxicity died from EFV-related hepatotoxicity, 1 of whom was symptomatic. The incidence of liver-related mortality was 0.07 (95% CI, .06-.08) per 100 person-years. In multivariable analysis, older age was associated with severe hepatotoxicity (adjusted hazard ratio per 5 years, 1.35 [95% CI, 1.06-1.70]). CONCLUSIONS:Severe hepatotoxicity after EFV initiation occurred in 2.5% of women and liver-related mortality occurred in 3% of those with severe hepatotoxicity. The occurrence of fatal events underscores the need for safer treatments for women of childbearing age.
RCT Entities:
BACKGROUND: Severe hepatotoxicity in people with human immunodeficiency virus (HIV) receiving efavirenz (EFV) has been reported. We assessed the incidence and risk factors of hepatotoxicity in women of childbearing age initiating EFV-containing regimens. METHODS: In the Promoting Maternal and Infant Survival Everywhere (PROMISE) trial, ART-naive pregnant women with HIV and CD4 count ≥ 350 cells/μL and alanine aminotransferase ≤ 2.5 the upper limit of normal were randomized during the antepartum and postpartum periods to antiretroviral therapy (ART) strategies to assess HIV vertical transmission, safety, and maternal disease progression. Hepatotoxicity was defined per the Division of AIDS Toxicity Tables. Cox proportional hazards models were constructed with covariates including participant characteristics, ART regimens, and timing of EFV initiation. RESULTS: Among 3576 women, 2435 (68%) initiated EFV at a median 121.1 weeks post delivery. After EFV initiation, 2.5% (61/2435) had severe (grade 3 or higher) hepatotoxicity with an incidence of 2.3 (95% confidence interval [CI], 2.0-2.6) per 100 person-years. Events occurred between 1 and 132 weeks postpartum. Of those with severe hepatotoxicity, 8.2% (5/61) were symptomatic, and 3.3% (2/61) of those with severe hepatotoxicity died from EFV-related hepatotoxicity, 1 of whom was symptomatic. The incidence of liver-related mortality was 0.07 (95% CI, .06-.08) per 100 person-years. In multivariable analysis, older age was associated with severe hepatotoxicity (adjusted hazard ratio per 5 years, 1.35 [95% CI, 1.06-1.70]). CONCLUSIONS: Severe hepatotoxicity after EFV initiation occurred in 2.5% of women and liver-related mortality occurred in 3% of those with severe hepatotoxicity. The occurrence of fatal events underscores the need for safer treatments for women of childbearing age.
Authors: Ian Sanne; Herve Mommeja-Marin; John Hinkle; John A Bartlett; Michael M Lederman; Gary Maartens; Charles Wakeford; Audrey Shaw; Joseph Quinn; Robert G Gish; Franck Rousseau Journal: J Infect Dis Date: 2005-02-10 Impact factor: 5.226
Authors: Sarah J Clark; Sarah Creighton; Bernard Portmann; Christopher Taylor; Julia A Wendon; Matthew E Cramp Journal: J Hepatol Date: 2002-02 Impact factor: 25.083
Authors: Zara Shubber; Alexandra Calmy; Isabelle Andrieux-Meyer; Marco Vitoria; Françoise Renaud-Théry; Nathan Shaffer; Sally Hargreaves; Edward J Mills; Nathan Ford Journal: AIDS Date: 2013-06-01 Impact factor: 4.177
Authors: Ferdinand W N M Wit; Gerrit Jan Weverling; Jan Weel; Suzanne Jurriaans; Joep M A Lange Journal: J Infect Dis Date: 2002-06-14 Impact factor: 5.226
Authors: Judith S Currier; Paula Britto; Risa M Hoffman; Sean Brummel; Gaerolwe Masheto; Esau Joao; Breno Santos; Linda Aurpibul; Marcelo Losso; Marie F Pierre; Adriana Weinberg; Devasena Gnanashanmugam; Nahida Chakhtoura; Karin Klingman; Renee Browning; Anne Coletti; Lynne Mofenson; David Shapiro; Jose Pilotto Journal: PLoS One Date: 2017-05-10 Impact factor: 3.240